Isotype
Whole Humanized Antibody
Description
CDC-Enhanced Pertuzumab is a Fc-modified anti-HER2 therapeutic biobetter antibody. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Pertuzumab, Pertuzumab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Early Breast Cancer
Inflammatory carcinoma of the breast
Locally Advanced Breast Cancer (LABC)
Metastatic Breast Cancer
Classification
Therapeutic antibody; biobetter
Patent
The patents on Herceptin will expire in the US in June 2019 and expired in Europe in July 2014.
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Pertuzumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Full Name
erb-b2 receptor tyrosine kinase 2
Background
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
Alternative Names
NEU; NGL; HER2; TKR1; CD340; HER-2; MLN 19; HER-2/neu
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
Whole Humanized Antibody
Description
Pertuzumab (also known as 2C4, trade name Perjeta) is a recombinant humanized monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 protein (HER2). It was first approved by the FDA in 2012 for the treatment of metastatic HER2-positive breast cancer; in early HER2-positive breast cancer, it is also used in the same combination as a new adjuvant. It was originally discovered and developed by Roche's subsidiary Genentech.
Indication
Early Breast Cancer
Inflammatory carcinoma of the breast
Locally Advanced Breast Cancer (LABC)
Metastatic Breast Cancer
Synonyms
2C4 Antibody
MOAB 2C4
Monoclonal Antibody 2C4
Omnitarg
rhuMAb-2C4
